Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Apr 2014

Mendes Rodrigo E, Deshpande Lalitagauri M, Jones Ronald N

Abstract excerpt

Linezolid, approved for clinical use since 2000, has become an important addition to the anti-Gram-positive infection armamentarium. This oxazolidinone drug has in vitro and in vivo activity against essentially all Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The in vitro activity of linezolid was well documented prior to its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Drug Approval

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gram-Positive Bacteria

Share to Gram-Positive Bacterial Infections

Share to Linezolid

Share to Oxazolidinones

Share to RNA, Ribosomal, 23S

Share to Tetrazoles

Source

Identifiers

PMID: 24880801
DOI: 10.1016/j.drup.2014.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.PMID 24880801Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesSemantic proximity Read ↗

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Semantic proximity Read ↗

The emerging problem of linezolid-resistant <i>Staphylococcus</i>Semantic proximity Read ↗

Linezolid: a review of its properties, function, and use in critical care.Semantic proximity Read ↗

Oxazolidinones: activity, mode of action, and mechanism of resistance.Semantic proximity Read ↗

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.Semantic proximity Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Semantic proximity Read ↗

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates.Semantic proximity Read ↗

The emerging problem of linezolid-resistant enterococci.Semantic proximity Read ↗

Tedizolid for the Management of Human Infections: In Vitro CharacteristicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.